News

Monthly Prescribing Reference7y
Verzenio Gains Expanded Breast Cancer Indication - MPR
Verzenio Gains Expanded Breast Cancer Indication. Da Hee Han, PharmD | February 27, 2018 . The approval of Verzenio as initial therapy in combination with an aromatase inhibitor is based ...
Drug Store News1y
FDA OKs new indication for Eli Lilly’s Verzenio
Verzenio is a targeted treatment known as a CDK4/6 inhibitor. Verzenio is a nonchemotherapy oral tablet. [Read more: Gilead’s Trodelvy receives FDA nod for new indication] ...
Nasdaq3y
FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer - Nasdaq
Verzenio is indicated for the treatment of HR+ HER2- advanced or metastatic breast cancer: in combination with an aromatase inhibitor for postmenopausal women, and men, as initial endocrine-based ...
Business Insider5y
Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer - Markets Insider
INDIANAPOLIS, June 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with standard ...